



MerLion Pharmaceuticals GmbH

Robert-Roessle-Str. 10

13125 Berlin

Germany

Phone +49 (0)30 94 89 – 40 50

Fax +49 (0)30 94 89 – 40 51

Email [info@merlionpharma.de](mailto:info@merlionpharma.de)

Internet [www.merlionpharma.com](http://www.merlionpharma.com)

MerLion Pharmaceuticals GmbH, Robert-Roessle-Str. 10, 13125 Berlin

12<sup>th</sup> October 2009

To whom it may concern,

Study FINA-004 has been withdrawn by the Sponsor (MerLion Pharmaceuticals GmbH). MerLion, at this time, is not able to continue the development of finafloxacin for the therapeutic indication of *Helicobacter pylori* infection beyond this study. MerLion has therefore determined that study FINA-004 will be ended early, prior to the study commencing. As the study has not yet started, (no sites have been initiated and thus no patients recruited), MerLion can therefore confirm that this action does not result from any safety concerns from other studies, neither does it impact on the risk-benefit assessment of finafloxacin, nor directly impact patients safety or treatment.

It is our intention to continue the clinical development of finafloxacin and to make further submissions at a future date in this or other therapeutic indications.

Please do not hesitate to contact me if you require further information.

Yours Sincerely

Harald Labischinski

Managing Director

Managing Director

Prof. Dr. Harald Labischinski

Trade register

HRB 112811 B  
Amtsgericht Charlottenburg  
TIN 37/491/20589  
VAT DE 211874455

bank account

Deutsche Bank Berlin  
Acct.No. 508 503 0, BIC 100 700 00  
IBAN: DE35100700000508503000  
BIC: DEUTDE33XXX